Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms

Inohara, Hidenori; Honjo, Yuichiro; Yoshii, Tadashi; Akahani, Shiro; Yoshida, Jun‐ichi; Hattori, Kenji; Okamoto, Shigeru; Sawada, Toru; Raz, Avraham; Kubo, Takeshi

doi:10.1002/(sici)1097-0142(19990601)85:11<2475::aid-cncr25>3.3.co;2-t

Cited by 27 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Different reports have shown downregulation of galectin-3 expression in cytoplasm of ovary, uterus, and breast carcinomas (van den Brule et al 1994(van den Brule et al , 1996Castronovo et al 1996). On the other hand, other authors have demonstrated that cytoplasmic galectin-3 expression is upregulated in cancers of tongue, thyroid, liver, stomach, central nervous system, and colon (Lotan et al 1994;Xu et al 1995;Bresalier et al 1997;Hsu et al 1999;Inohara et al 1999;Honjo et al 2000). It still remains unclear why the regulation of galectin-3 expression is different in various organs during neoplastic progression.…”

Section: Discussionmentioning

confidence: 98%

Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster

Saussez

Nonclercq

Laurent

et al. 2004

Histochem Cell Biol

View full text Add to dashboard Cite

The current study focused on galectins (-1, -3, -4, -7, and -8) and deliberately performed immunohistochemical fingerprinting to explore their complexity in a context of experimental renal carcinogenesis. The diethylstilbestrol (DES)-induced renal tumors in male Syrian hamster kidney (SHKT) represent a unique animal model for the study of estrogen-dependent renal malignancies. Kidney sections of DES-treated hamsters (3 days to 11 months of DES exposure) were analyzed by immunohistochemistry using a panel of non-crossreactive antibodies raised against galectins-1, -3, -4, -7, and -8. Levels of expression were quantitatively determined by using computer-assisted microscopy on immunostained tissue sections. Except for galectin-4, all above mentioned galectins were expressed in kidney tumors. Small clusters of galectin-1-positive, most likely preneoplastic cells at the corticomedullary junction were already evident 1 week after DES administration. Galectin-1 and -3 expression was apparently associated with the first steps of the neoplastic transformation, because small tumorous buds were found to be positive after 1 month of treatment. In contrast, galectins-7 and -8 were detected in large tumors and medium-sized tumors, respectively, thereby indicating an involvement in later stages of DES-induced SHKT. Galectins-1, -3, -7, and -8 were also detected by immunofluorescence staining in the HKT-1097 cell line established from SHKT, thus illustrating the stability of galectin expression in tumor cells. Our data document the presence and differential regulation of galectins in the course of renal tumorigenesis in the model of DES-induced SHKT.

show abstract

Section: Discussionmentioning

confidence: 98%

Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster

Saussez

Nonclercq

Laurent

et al. 2004

Histochem Cell Biol

View full text Add to dashboard Cite

show abstract

“…When compared with their normal tissue counterparts, altered expression of gal-3 in human tumors has been documented for many tumor types (reviewed by Danguy et al 2002 andvan den Brule et al 2004). Overexpression of gal-3 has been demonstrated in thyroid carcinomas, in both histologic sections (Xu et al 1995;Fernández et al 1997;Cvejic et al 1998) and cytologic specimens (Orlandi et al 1998;Inohara et al 1999;Bartolazzi et al 2001;Saggiorato et al 2001), whereas its expression in nonmalignant thyroid cells was absent or weak. Overexpression of gal-3 has also been found in serum from patients with breast, gastrointestinal, lung, ovarian cancer, melanoma and non-Hodgkin's lymphoma, when compared with sera from normal subjects (Iurisci et al 2000).…”

Section: Introductionmentioning

confidence: 99%

Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors

Isic

Savin

Cvejić

et al. 2010

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

While CK19 and gal-3 are accurate as tissue markers, their serum levels could not be used as reliable markers for identification of thyroid malignancy or in thyroid cancer follow-up. On the other hand, a tendency toward higher serum levels of Cyfra 21.1 in the small number of PDTC patients examined adds weight to previous reports postulating a role for cytokeratins in predicting a high degree of malignancy.

show abstract

“…Regarding HBME-1, the negativity is the rule [24][25][26][27]. Galectine-3 is usually positive but the staining is often described as less intense than in papillary carcinoma [25,[27][28][29][30][31][32][33][34]. In the three cases of pure papillary carcinoma, pleomorphic giant cells were negative for p53.…”

Section: Discussionmentioning

confidence: 99%

Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma

et al. 2010

View full text Add to dashboard Cite

The presence of pleomorphic tumor giant cells in thyroid carcinomas of follicular cell origin is always worrisome for the pathologist as they first of all refer to anaplastic carcinoma, one of the most aggressive human malignancies. However, non-anaplastic pleomorphic giant cells are well described in other thyroid diseases, most often benign. In this paper, we describe four cases of papillary thyroid carcinoma displaying pleomorphic tumor giant cells with features that differ from those of anaplastic carcinoma. Pleomorphic giant cells were admixed with the underlying thyroid carcinoma and constituted from 5% to 25% of the tumor. Cytologically, they had an abundant eosinophilic cytoplasm with large and irregular nuclei. Compared to pleomorphic giant cells of anaplastic carcinoma, they reproduced the growth pattern of the underlying carcinoma, had a low mitotic index without necrosis or inflammation, and were reactive with thyroglobulin and thyroid-specific transcription factor-1 and strongly and diffusely positive for cytokeratin AE1/AE3. After 16-84 months of follow-up, patients are relapse-free and still alive. These cases show that pleomorphic tumor giant cells arising in papillary thyroid carcinomas do not always represent dedifferentiation and progression to anaplastic carcinoma. Distinction among these processes is critical as their treatment and prognosis are very different.

show abstract

Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms

Abstract: Galectin-3 serves as a marker of thyroid malignancy of follicular cell origin. Analysis of galectin-3 expression in fine-needle aspirates enhances the differential diagnostic accuracy between benign and malignant thyroid neoplasms.

Cited by 27 publications

References 0 publications

Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster

Toward functional glycomics by localization of tissue lectins: immunohistochemical galectin fingerprinting during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster

Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors

Nonconventional papillary thyroid carcinomas with pleomorphic tumor giant cells: a diagnostic pitfall with anaplastic carcinoma

Contact Info

Product

Resources

About